|
EP3341007B1
(en)
|
2015-08-28 |
2020-12-23 |
Cornell University |
Malt1 inhibitors and uses thereof
|
|
JP2018533610A
(ja)
*
|
2015-11-13 |
2018-11-15 |
ノバルティス アーゲー |
新規なピラゾロピリミジン誘導体
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP3592731A4
(en)
*
|
2017-03-08 |
2020-10-07 |
Cornell University |
MALT1 INHIBITORS AND THEIR USES
|
|
EP3641762B1
(en)
|
2017-06-20 |
2026-02-18 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
SG11202006200RA
(en)
|
2017-12-28 |
2020-07-29 |
Massachusetts Gen Hospital |
Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
|
|
KR20210018199A
(ko)
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
|
ES2965174T3
(es)
|
2018-04-12 |
2024-04-11 |
Bayer Ag |
Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}heterociclilamida y compuestos similares como plaguicidas
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
FI3784663T3
(fi)
|
2018-04-23 |
2023-10-06 |
Celgene Corp |
Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
|
|
SG11202010068VA
(en)
|
2018-04-25 |
2020-11-27 |
Bayer Ag |
Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
WO2019242625A1
(zh)
*
|
2018-06-20 |
2019-12-26 |
上海科技大学 |
制备来那度胺衍生物的方法
|
|
WO2020111087A1
(ja)
|
2018-11-28 |
2020-06-04 |
武田薬品工業株式会社 |
複素環化合物
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
CA3133314A1
(en)
|
2019-03-21 |
2020-09-24 |
Codiak Biosciences, Inc. |
Extracellular vesicle conjugates and uses thereof
|
|
US12233356B2
(en)
|
2019-03-21 |
2025-02-25 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
US12624015B2
(en)
|
2019-06-24 |
2026-05-12 |
University Of Iowa Research Foundation |
JNK inhibitors as anticancer agents
|
|
EP3986397A4
(en)
*
|
2019-06-24 |
2023-05-10 |
Dana-Farber Cancer Institute, Inc. |
HCK DEGRADERS AND USES THEREOF
|
|
PH12022550166A1
(en)
|
2019-07-23 |
2022-11-14 |
Bayer Ag |
Novel heteroaryl-triazole compounds as pesticides
|
|
EP4041393B1
(en)
|
2019-10-09 |
2026-04-08 |
Bayer Aktiengesellschaft |
Novel heteroaryl-triazole compounds as pesticides
|
|
WO2021127586A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase degraders and methods of use thereof
|
|
IL294214B2
(en)
*
|
2019-12-27 |
2026-04-01 |
Schrodinger Inc |
Cyclic compounds and methods for using them
|
|
CN115835886A
(zh)
*
|
2020-04-23 |
2023-03-21 |
衣阿华大学研究基金会 |
Gper蛋白水解靶向嵌合体
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
US20230192685A1
(en)
*
|
2020-05-27 |
2023-06-22 |
Takeda Pharmaceutical Company Limited |
Method for producing heterocyclic compound
|
|
AU2021293907A1
(en)
*
|
2020-06-17 |
2023-01-19 |
Dana-Farber Cancer Institute, Inc. |
Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
|
|
US20230235077A1
(en)
|
2020-06-24 |
2023-07-27 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
EP4243812A1
(en)
*
|
2020-11-12 |
2023-09-20 |
Monopteros Therapeutics, Inc. |
Materials and methods of treating cancer
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
EP4285124A4
(en)
*
|
2021-01-29 |
2025-01-08 |
Eurofins DiscoverX Corporation |
MOLECULAR GLUE SCREENING ASSAYS AND METHODS OF IMPLEMENTATION THEREOF
|
|
IL313925A
(en)
|
2021-12-30 |
2024-08-01 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Inhibitor of tricyclic derivatives, method of preparation therefor and application
|
|
CN118591541A
(zh)
*
|
2022-01-18 |
2024-09-03 |
奥瑞基尼肿瘤有限公司 |
作为malt-1抑制剂的经取代的双环杂环
|
|
CN118525021A
(zh)
*
|
2022-01-28 |
2024-08-20 |
上海齐鲁制药研究中心有限公司 |
靶向malt1的蛋白降解化合物
|
|
KR20240144146A
(ko)
|
2022-02-02 |
2024-10-02 |
오노 야꾸힝 고교 가부시키가이샤 |
Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
|
|
US20250163066A1
(en)
*
|
2022-02-25 |
2025-05-22 |
Tegid Therapeutics, Inc. |
PROTACs of MALT1
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|